Production costs and potential prices for biosimilars of human insulin and insulin analogues

Volume: 3, Issue: 5, Pages: e000850 - e000850
Published: Sep 1, 2018
Abstract
Introduction High prices for insulin pose a barrier to treatment for people living with diabetes, with an estimated 50% of 100 million patients needing insulin lacking reliable access. As insulin analogues replace regular human insulin (RHI) globally, their relative prices will become increasingly important. Three originator companies control 96% of the global insulin market, and few biosimilar insulins are available. We estimated the price...
Paper Details
Title
Production costs and potential prices for biosimilars of human insulin and insulin analogues
Published Date
Sep 1, 2018
Volume
3
Issue
5
Pages
e000850 - e000850
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.